World Health Organization site
Skip Navigation Links

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Last refreshed on: 16 December 2017
Main ID:  NCT03151525
Date of registration: 08/05/2017
Prospective Registration: Yes
Primary sponsor: Istituto Clinico Humanitas
Public title: Two Therapeutic Strategies for the Maintenance of Remission in Patients With Ulcerative Colitis SCILLA
Scientific title: Comparison Between Two Therapeutic Strategies for the Maintenance of Clinical and Endoscopic Remission in Patients With Ulcerative Colitis Treated by Infliximab
Date of first enrolment: May 8, 2017
Target sample size: 100
Recruitment status: Recruiting
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).  
Phase:  Phase 4
Countries of recruitment
Name:     Silvio Danese, MD, PhD
Telephone: 0039028224
Name:     Silvio Danese, MD, PhD
Telephone: +390282245555
Key inclusion & exclusion criteria

Inclusion Criteria:

- Age 18 -65 years

- Written informed consent and willing to adhere to study procedures.

- Therapy with infliximab since at least 12 months, with one infusion every 8 weeks (a
maximum interval between two infusions of ± 3 weeks is allowed)

- Sustained steroid-free remission in the last 6 months prior to inclusion, except for
use of steroids as a preventive measure for infliximab infusion reaction, if required
by local guidelines.

- Global Mayo score at baseline = 2

- All Mayo subscores = 1

- Absence of rectal bleeding

- Effective methods to avoid pregnancy during the study period

Exclusion Criteria:

- Disabling and persisting extraintestinal manifestation at baseline

- Patients unable to comply with study procedures

- Known intolerance or previous allergic reaction to thiopurines

- Concomitant therapy with allopurinol

- Any disease not compatible with the use of infliximab or azathioprine, as per
clinician's judgement.

- Need for dose escalation of infliximab in the last 12 months prior to baseline.

- White blood cell count < 3000/mmc or absolute clinically relevant lymphopenia at

- Active pregnancy or breastfeeding; willing for pregnancy during the study period

Age minimum: 18 Years
Age maximum: 65 Years
Gender: All
Health Condition(s) or Problem(s) studied
Colitis, Ulcerative
Drug: Azathioprine
Drug: Infliximab
Primary Outcome(s)
Relapse rate [Time Frame: 12 months]
Secondary Outcome(s)
Identification of potential risk factors for relapse. Age, sex, smoking habits, histological healing of mucosa and each Mayo subscore at baseline will be examined [Time Frame: 12 months]
Number of adverse events [Safety and Tolerability] [Time Frame: 12 months]
Number of serious adverse events [Safety and Tolerability] [Time Frame: 12 months]
Relapse time [Time Frame: 12 months]
Secondary ID(s)
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Agenzia Italiana del Farmaco
Ethics review
Results available:
Date Posted:
Date Completed:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history